Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OliPass NOX4 PNA
- Development stage
- Preclinical
- Lead developer
- OliPass
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Ophthalmic, Oral
01
Overview
OliPass NOX4 PNA is an antisense oligonucleotide (ASO) being developed by OliPass for the treatment of fibrosis. The therapeutic utilizes OliPass's proprietary Peptide Nucleic Acid (PNA) platform, which incorporates modified chemical structures to enhance cellular uptake and binding affinity to target RNA. The drug operates through an exon-skipping mechanism to downregulate the expression of NADPH oxidase 4 (NOX4). NOX4 is a key enzyme responsible for generating reactive oxygen species (ROS), which drive myofibroblast activation and extracellular matrix deposition in various fibrotic conditions. The program is currently in the research and preclinical development stage.
- Other names
- OliPass-NOX4-antisense oligonucleotide (PNA)-FibrosisNOX4 antisense oligonucleotideNOX-4 antisense oligonucleotideNOX 4 antisense oligonucleotideNOX4-PNANOX-4-PNANOX 4-PNA
02
Targets
NOX4 (NADPH oxidase 4)
Beyond the preview
Go deeper on OliPass NOX4 PNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OliPass NOX4 PNA.